CN102498110A - 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 - Google Patents

作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Download PDF

Info

Publication number
CN102498110A
CN102498110A CN2010800358308A CN201080035830A CN102498110A CN 102498110 A CN102498110 A CN 102498110A CN 2010800358308 A CN2010800358308 A CN 2010800358308A CN 201080035830 A CN201080035830 A CN 201080035830A CN 102498110 A CN102498110 A CN 102498110A
Authority
CN
China
Prior art keywords
amino
bases
pyrazoles
pyrimidine
formamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800358308A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·柯丁
M·R·麦克利德斯
H·R·海曼
R·R·弗里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CN102498110A publication Critical patent/CN102498110A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800358308A 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Pending CN102498110A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18575809P 2009-06-10 2009-06-10
US61/185758 2009-06-10
PCT/US2010/037801 WO2010144468A1 (en) 2009-06-10 2010-06-08 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102498110A true CN102498110A (zh) 2012-06-13

Family

ID=42333314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800358308A Pending CN102498110A (zh) 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶

Country Status (7)

Country Link
US (1) US8426408B2 (enExample)
EP (1) EP2440548A1 (enExample)
JP (1) JP2012529522A (enExample)
CN (1) CN102498110A (enExample)
CA (1) CA2764983A1 (enExample)
MX (1) MX2011013325A (enExample)
WO (1) WO2010144468A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926824A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
BR112013011600B1 (pt) * 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
SG194086A1 (en) * 2011-04-22 2013-11-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
JP6218808B2 (ja) * 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
JP6360881B2 (ja) * 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
US10273224B2 (en) 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP6517319B2 (ja) * 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2016060963A1 (en) * 2014-10-14 2016-04-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
SG11201704827UA (en) 2014-12-16 2017-07-28 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017048675A1 (en) * 2015-09-17 2017-03-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374301A (en) 1990-07-26 1994-12-20 Zeneca Limited Inks suitable for use in ink jet printing
GB9303912D0 (en) 1993-02-26 1993-04-14 Zeneca Ltd Inks
JP3880076B2 (ja) 1994-02-25 2007-02-14 キヤノン株式会社 インク、インクジェット記録方法、記録ユニット、インクカートリッジ及びインクジェット記録装置
JPH08113744A (ja) 1994-08-25 1996-05-07 Canon Inc インク、これを用いたインクジェット記録方法及びかかるインクを備えた記録機器
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
US6117996A (en) 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
JP3106966B2 (ja) 1996-07-17 2000-11-06 富士ゼロックス株式会社 インクジェット記録用インク及びインクジェット記録方法
JPH1060338A (ja) 1996-08-21 1998-03-03 Fuji Xerox Co Ltd インクジェット記録用インク及びインクジェット記録方法
US5980623A (en) 1997-01-29 1999-11-09 Fuji Xerox Co., Ltd. Ink set for ink jet recording and ink jet recording method
JP3829419B2 (ja) 1997-07-09 2006-10-04 三菱化学株式会社 カラー画像の形成方法
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DK2287156T3 (da) * 2003-08-15 2013-08-26 Novartis Ag 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7812166B2 (en) 2004-10-29 2010-10-12 Abbott Laboratories Kinase inhibitors
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
MX2007005857A (es) * 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1841760B1 (en) * 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8501939B2 (en) 2005-06-10 2013-08-06 Prometic Biosciences Limited Triazines and pyrimidines as protein binding ligands
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926824A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926794A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926795A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926824B (zh) * 2014-03-17 2017-07-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926794B (zh) * 2014-03-17 2017-12-05 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2018086547A1 (zh) * 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途

Also Published As

Publication number Publication date
WO2010144468A1 (en) 2010-12-16
CA2764983A1 (en) 2010-12-16
US20100317680A1 (en) 2010-12-16
US8426408B2 (en) 2013-04-23
MX2011013325A (es) 2012-04-30
JP2012529522A (ja) 2012-11-22
EP2440548A1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
CN102498110A (zh) 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶
US8293738B2 (en) Indazole inhibitors of kinase
TWI500621B (zh) 具改良ｃｙｐ安全性之激酶抑制劑
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
MX2012013196A (es) Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.
KR20110102473A (ko) 헤테로시클릭 화합물 및 사용 방법
US20140155389A1 (en) Bicyclic inhibitors of alk
CN102459236B (zh) 激酶活性的嘧啶抑制剂
CN104011049A (zh) 激酶的吡啶并嘧啶酮抑制剂
US8859546B2 (en) Picolinamide inhibitors of kinases
US9212192B2 (en) Bicyclic carboxamide inhibitors of kinases
CN109422749A (zh) 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN103415516A (zh) Alk的双环抑制剂
US8436179B2 (en) Kinase inhibitor with improved solubility profile
CN103443102A (zh) 激酶的双环甲酰胺抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130618

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

AD01 Patent right deemed abandoned

Effective date of abandoning: 20120613

C20 Patent right or utility model deemed to be abandoned or is abandoned